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Endothelial injury with failure of pulmonary endothelium-dependent 
vasodilatation has been proposed as a possible cause for the increased 
pulmonary vascular esistance observed after cardiopulmonary b pass, but 
the mechanisms underlying this response are not understood. An in vivo 
piglet model was used to investigate the role of endothelium-dependent 
vasodilatation in postbypass pulmonary hypertension. The pulmonary 
vascular responses to acetylcholine, a receptor-mediated ndothelium- 
dependent vasodilator, and nitric oxide, an endothelium-independent va- 
sodilator, were studied in one group of animals after preconstriction with 
the thromboxane A2 analog U46619 (n = 6); a second group was studied 
after bypass with 30 minutes of deep hypothermic circulatory arrest (n = 
6). After preconstriction with U46619, both acetylcholine and nitric oxide 
caused significant decreases in pulmonary vascular esistance (34% +- 6% 
decrease, p --- 0.007, and 39% -- 4% decrease, p = 0.001). After cardiopul- 
monary bypass with circulatory arrest, acetylcholine did not significantly 
change pulmonary vascular resistance (0% +-- 8% decrease, p = 1.0), 
whereas nitric oxide produced a 32% +-- 4% decrease in pulmonary vascular 
resistance (p = 0.007). These results demonstrate a loss of receptor- 
mediated endothelium-dependent vasodilatation wi h ormal vascular 
smooth muscle function after circulatory arrest. Administration of the 
nitric oxide synthase blocker N3,-nitro-L-arginine-methyl-ester af circu- 
latory arrest significantly increased pulmonary vascular esistance; thus, 
although endothelial cell production of nitric oxide may be diminished, it 
continues to be a major contributor to pulmonary vasomotor tone after 
cardiopulmonary bypass with deep hypothermic irculatory arrest. In 
summary, cardiopulmonary bypass with deep hypothermic irculatory 
arrest results in selective pulmonary endothelial cell dysfunction with loss 
of receptor-mediated ndothelium-dependent vasodilatation despite pre- 
served ability of the endothelium to produce nitric oxide and intact vascular 
smooth muscle function. (J Thorac Cardiovasc Surg 1996;111:1248-56) 
p ulmonary hypertension associated with elevated 
pulmonary vascular esistance (PVR) can be a 
significant problem after the use of cardiopulmo- 
nary bypass (CPB) with deep hypothermic circula- 
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tory arrest (DHCA) for the repair of congenital 
cardiac disease. 1-3 Pulmonary vasomotor tone is 
determined by the balance between competing ef- 
fects of vasoconstrictors and vasodilators. The en- 
dothelium produces vasoconstrictors and vasodila- 
tors that affect pulmonary vasomotor tone; however, 
the factors that modulate PVR in vivo have not been 
fully delineated. The vasodilator nitric oxide is pro- 
duced by endothelial cells from the precursor amino 
acid L-arginine and is important in the maintenance 
of the normally low PVR. ~ Endothelium-dependent 
vasodilators, such as acetylcholine, stimulate endo- 
thelial production of vasodilating agents, the most 
significant of which is nitric oxide. Endothelium- 
independent vasodilators, such as inhaled nitric 
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Fig. 1. Endothelium-dependent vasodilation. Acetylcholine binds to the muscarinic receptor (MR) 
triggering an increase in cytosolic calcium (Ca + +) concentrations through aG protein (GP)-phospholipase 
C (PLC) second messenger system. Nitric oxide synthase (NOS) is stimulated by the increase in Ca --+ 
resulting in increased nitric oxide production from L-arginine (L-arg). Nitric oxide (NO) diffuses into the 
vascular smooth muscle cell and stimulates guanylate cyclase (GC), which converts guanosine triphosphate 
(GTP) to cyclic guanosine monophosphate (cGMP). Cyclic guanosine monophosphate then triggers 
smooth muscle cell relaxation. 
oxide or sodium nitroprusside, act directly on the 
vascular smooth muscle. Endothelial dysfunction, 
manifested as impaired endothelium-dependent 
pulmonary vasodilatation i response to acetylcho- 
line, has been documented in children after CPB. a 
Decreased responsiveness to endothelium-depen- 
dent vasodilators after CPB has been postulated to 
result from a loss of nitric oxide production resulting 
from endothelial cell injury; however, the mecha- 
nisms involved remain unclear. 
Endothelium-dependent vasodilators can be clas- 
sified as either eceptor-mediated or receptor-inde- 
pendent agents. Receptor-mediated vasodilators, in- 
cluding acetylcholine and adenosine diphosphate, 
act via their receptor located on the endothelial cell 
surface to stimulate nitric oxide production. Recep- 
tor-independent endothelium-dependent agents, in- 
cluding phospholipase C and the calcium ionophore 
A23187, do not act through amembrane r ceptor to 
stimulate nitric oxide production, s Acetylcholine 
provides a useful paradigm for receptor-mediated 
endothelium-dependent vasodilatation (Fig. 1), 5,6 
with the muscarinic receptor on the endothelial cell 
surface linked to production of nitric oxide through 
a guanine nucleotide regulatory protein or G pro- 
tein. G proteins are heterotrimeric membrane-asso- 
ciated proteins that transduce receptor-generated 
signals to second messenger systems, which then 
alter cellular activity. 6In vascular endothelial cells, 
stimulation of the muscarinic receptor-G protein 
complex activates the production of inositol triphos- 
phate by phospholipase C, which triggers an in- 
crease in the cytosolic calcium ion concentration. 
Nitric oxide synthase activity is increased by eleva- 
tions in cytosolic alcium in endothelial cells, result- 
ing in increased production of nitric oxide from 
I~-arginine. Nitric oxide then diffuses into the adja- 
cent vascular smooth muscle and stimulates guany-. 
late cyclase, which converts guanosine triphosphate 
to cyclic guanosine monophosphate. Increased lev- 
els of cyclic guanosine monophosphate r sult in 
smooth muscle cell relaxation. Failure of any step in 
this sequence could result in decreased receptor- 
mediated endothelium-dependent vasodilatation. 
The current study was undertaken toevaluate the 
mechanisms underlying diminished receptor-medi- 
ated endothelium-dependent vasodilatation after 
CPB in an in vivo animal model. Validation of the 
model requires demonstration f normal endothe- 
lial and vascular smooth muscle function before 
CPB and failure of receptor-mediated en othelium- 
dependent vasodilatation after CPB. 
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Materials and methods 
Anesthesia and surgery. Forty DeKalb piglets (4 to 6 
weeks old and weighing 9 to 13 kg) were studied in four 
separate protocols. All animals received humane care in 
accordance with the "Guide for the Care and Use of 
Laboratory Animals" published by the National Institutes 
of Health (NIH publication No. 85-23, revised 1985) and 
as approved by the Duke University Medical Center 
Animal Care and Use Committee. The same anesthesia 
and CPB techniques were used for the three experiments. 
Anesthesia was induced with intramuscular ketamine 
(20 mg/kg) and acepromazine (1 mg/kg). The piglets were 
intubated and mechanical ventilation (Sechrist Infant 
Ventilator, model IV-100B, Sechrist Industries, Inc., Ana- 
heim, Calif.) was begun. Anesthesia was maintained with 
fentanyl (100/~g/kg bolus and 50/~g/kg per hour contin- 
uous infusion) and pancuronium (0.3 ~g/kg). The venti- 
lator was set with a positive inspiratory pressure of 25 mm 
Hg and a positive end-expiratory pressure of 3 mm Hg. 
Respiratory rate and inspired oxygen fraction were ti- 
trated to maintain an arterial carbon dioxide tension of 35 
to 45 mm Hg and an oxygen tension of 150 to 250 mm Hg. 
Sodium bicarbonate (8.5%) was used to maintain a base 
excess between -3  and 3 mmol/L. All animals received 
methylprednisolone (25 mg/kg intravenously) before the 
operation. 
A femoral arterial ine was placed for blood pressure 
monitoring and arterial blood gas sampling. A nasopha- 
ryngeal temperature probe (Yellow Springs Instrument 
Company, Yellow Springs, Ohio, YSI-400) was inserted 
and a median sternotomy was performed. The pericar- 
dium was opened and a 10 mm ultrasonic flow probe was 
placed on the main pulmonary artery (Transonic Systems 
Inc., Ithaca, N.Y.). Micromanometers (3F, Millar Instru- 
ments, Inc., Houston, Tex.) were placed in the pulmonary 
artery and left atrium and a 24-gauge infusion catheter 
was placed in the pulmonary artery. 
CPB. Purse-string sutures of 2-0 Silk and 5-0 Prolene 
polypropylene (Ethicon, Inc., Somerville, N.J.) were 
placed in the right atrial appendage and aortic root, 
respectively. Animals were given heparin (500 IU/kg) and 
cannulated with a 10F infant arterial cannula and a 28F 
venous cannula (Electro-catheter Corp., Rahway, N.J.). 
The CPB circuit consisted of a Stockert Shiley roller pump 
(Shiley Inc., Irvine, Calif., model 10-10-00), a Cobe mem- 
brane oxygenator (Cobe Laboratory, Lakewood, Colo.), 
and a Bio-Cal 370 heat exchanger (Medtronic Bio-Medi- 
cus, Minneapolis, Minn.). The pump was primed with 
crystalloid solution and fresh donor pig blood to maintain 
a circuit hematocrit value of 18% to 20%. 
The piglets were cooled over 20 minutes to a nasopha- 
ryngeal temperature of 18 ° C, the hearts were arrested for 
either 30 or 60 minutes, the animals were rewarmed over 
30 minutes to 37 ° C, and they were weaned from CPB. 
Saline slush was used for topical myocardial hypothermia 
during cooling and circulatory arrest. The hearts became 
asystolic during cooling and occasionally fibrillated uring 
rewarming, necessitating direct-current cardioversion with 
1 to 2 joules. No animal required more than two defibril- 
lations. CPB circuit volume was returned to the animals as 
needed to maintain astable left atrial pressure and cardiac 
output after weaning from CPB. No inotropic agents were 
used. Animals were studied 15 minutes after weaning 
from CPB while in a steady-state condition with arterial 
blood gases within the limits previously described in the 
Anesthesia nd surgery section. 
Assessment of endothelium-dependent a d endotheli- 
urn-independent vasodilatation. Receptor-mediated n- 
dothelium-dependent vasodflatation was assessed with a 
continuous infusion of acetylcholine ata rate of 12.5/xg/kg 
per minute into the pulmonary artery line. Data were 
acquired before and 5 minutes after the acetylcholine 
infusion was begun (5 minutes of infusion was found to be 
sufficient o achieve a steady-state effect in preliminary 
studies). 
Endothelium-independent vasodilatation was assessed 
with nitric oxide 10 minutes after discontinuation of 
acetylcholine (the amount of time that was determined in
preliminary studies to be sufficient for the animals to 
return to baseline). Data were collected immediately 
before and 5 minutes after institution of inhalational nitric 
oxide at twenty parts per million (ppm) through the 
ventilator circuit. Inhalational nitric oxide concentration 
was monitored with a chemiluminescence nitric oxide 
analyzer (model 42H, Thermo Environmental Instru- 
ments, Franklin, Mass.). Nitrogen dioxide concentrations 
were also monitored and did not exceed 1 ppm. 
Data collected included pulmonary artery and left atrial 
pressures, pulmonary artery flow (cardiac output), mean 
arterial pressure, heart rate, and arterial blood gases. 
Pressure and flow data were collected at 200 Hz over 10 
seconds with the ventilator placed at a 3 mm Hg contin- 
uous positive airway pressure. PVR was calculated with 
the following formula: 
PVR = (PAP - LAP)/CO × 1330 dynes/ram Hg 
where PAP = mean pulmonary artery pressure, LAP -- 
mean left atrial pressure, CO = cardiac output in millili- 
ters per second, and 1330 dynes/ram Hg is a constant that 
converts millimeters of mercury to dynes. 
Evaluation of endothelium-dependent and endotheli- 
um-independent vasodilatation before CPB (protocol 1). 
To demonstrate normal endothelium-dependent and -in- 
dependent vasodilatation i  normal animals, we assessed 
the responses to acetylcholine and nitric oxide in two 
experimental groups. Control animals (n = 5) were stud- 
ied with both drugs after anesthesia and instrumentation 
only; animals treated with U46619 (n = 6) were studied 
while receiving a continuous infusion of the thromboxane 
A2 analog U46619 to preconstrict the pulmonary vascula- 
ture. Normally the pulmonary vasculature is essentially 
maximally vasodilated; therefore preconstriction is neces- 
sary to demonstrate normal endothelial and smooth mus- 
cle function. 
U46619-treated animals received U46619 diluted in 
saline solution to a concentration of 2 /xg/ml through a 
pulmonary arterial infusion line. The U46619 dose was 
titrated to achieve a PVR between 1800 and 2100 dyne - 
sec • cm -5. This level of vasoconstriction was chosen after 
preliminary experiments demonstrating similar levels of 
PVR after CPB with DHCA. The mean dose was 0.07 -+ 
0.02/xg/kg per minute. 
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Endothelium-dependent and endothelium-independent 
vasodilatation after CPB with DHCA (protocol 2). To 
evaluate ndothelium-dependent and -independent vaso- 
dilatation after CPB with DHCA, we supported six ani- 
mals (DHCA) with CPB and arrested their hearts for 30 
minutes as previously described in the CPB section. 
Fifteen minutes after they were weaned from CPB, pul- 
monary vascular esponses to acetylcholine and nitric 
oxide were assessed as described earlier. 
Effect of nitric oxide synthase blockade before and after 
CPB (protocol 3). The nitric oxide synthase inhibitor Ny- 
nitro-I.-arginine-methyl-ester (L-NAME) was used to ex- 
amine the functional state of nitric oxide synthase in 
endothelial cells after CPB with DHCA. L-NAME is an 
analog of L-arginine and a competitive inhibitor of nitric 
oxide synthase. Administration of L-NAME results in 
pulmonary vasoconstriction ly if endothelial cells are 
actively producing nitric oxide, L-NAME/control animals 
(n = 6) were treated with L-NAME (5 mg/kg bolus via the 
pulmonary artery catheter) after anesthesia nd instru- 
mentation only. L-NAME/DHCA animals (n = 6) under- 
went CPB with 60 minutes of DHCA and were treated 
with L-NAME 15 minutes after being weaned from CPB. 
Data acquisition as described earlier was performed im- 
mediately before and 5, 10, 15, and 20 minutes after 
L-NAME was administered. 
Effects of L-arginine supplementation on post-CPB 
pulmonary hypertension (protocol 4). L-Arginine is the 
substrate for nitric oxide synthase and is necessary for the 
production of nitric oxide. A decrease in the availability of 
L-arginine to the endothelial cell after CPB could limit 
nitric oxide production and alter the balance between 
vasoconstrictors and vasodilators. To determine if sub- 
strate limitation is a factor in post-CPB pulmonary hyper- 
tension, the effects of L-arginine supplementation during 
CPB were evaluated. No-L-arginine animals (n = 6) 
underwent CPB with 60 minutes of DHCA with no 
additional treatment. L-Arginine (n = 5) animals under- 
went CPB with 60 minutes of DHCA and received a 
continuous infusion of L-arginine at 20 mg/kg per minute 
throughout the CPB period (but not during DHCA). Data 
were collected as described earlier both before CPB and 
15 minutes after weaning from CPB in both groups. 
Statistical analysis. Analysis of variance was used to 
compare data between groups followed by the unpaired 
two-tailed t tests. Ap value less than 0.05 was considered 
significant. Analysis of variance for repeated measures 
and Scheffe's post-hoc test were used to compare data 
within groups at different ime points. Paired t tests were 
used if only two time points were compared. Statistical 
analysis was performed with commercially available soft- 
ware (Statview I1, Abacus Concepts, Inc., Berkeley, Ca- 
lif.). All data are presented as means -+ standard error of 
the mean. 
Results 
Arterial blood gases and hemodynamic data. 
There were no significant differences in the arterial 
blood gases between the study and control groups in 
any of the protocols. Arterial blood gas data from 
the control, U46619, and DHCA groups (protocols 
1 and 2) are displayed in Table I. 
Cardiac outputs and mean pulmonary artery pres- 
sures for the four protocols are summarized in 
Tables I IA to I1C. Left atrial pressures were main- 
tained at 4 to 9 mm Hg with volume infusions and, 
although there was a trend toward higher left atrial 
pressure after DHCA, these differences did not 
achieve statistical significance. 
Endothclium-dependent and endothelium-inde- 
pendent vasodilatation before CPB (protocol 1). 
Piglets studied at baseline (controls) were essen- 
tially maximally vasodilated and did not respond to 
either nitric oxide or acetylcholine (Fig. 2, A). PVR 
was significantly elevated by U46619 infusion (545 ± 
49 vs 1817 ± 16i dyne. sec.  cm -5, baseline vs 
pre-acetylcholine, p = 0.0003). In the animals pre- 
constricted with U46619, both acetylcholine and 
nitric oxide caused significant pulmonary vasodila- 
tation with 34% + 6% (p = 0.007 pre-acetylcholine 
vs acetylcholine) and 39% + 4% (p = 0.001 pre- 
nitric oxide vs nitric oxide) decreases in PVR, 
respectively. These decreases in PVR demonstrate 
intact receptor-mediated endothelium-dependent and 
endothelium-independent vasodilatation (Fig. 2, B). 
Endothclium-dependent and endotheiium-inde- 
pendent vasodilatation after CPB with DHCA (pro- 
tocol 2). CPB with DHCA resulted in a significant 
increase in PVR from 704 + 68 to 1925 + 266 dyne 
• sec. cm -5 (p = 0.003). After CPB with DHCA, 
acetylcholine did not alter PVR, with a 0% -+ 8% 
change (p = 1.0 pre-acetylcholine vs acetylcholine), 
indicating failure of receptor-mediated endothelium- 
dependent vasodilatation; itric oxide caused a 32% + 
4% decrease in PVR (p = 0.007 pre-nitric oxide vs 
nitric oxide), demonstrating intact endothelium-inde- 
pendent vasodilatation and normal vascular smooth 
muscle function (Fig. 2, C). These data are consistent 
with previously reported clinical studies. 2'3 
Effect of nitric oxide synthase blockade before 
and after CPB (protocol 3). PVR increased signifi- 
cantly after DHCA (611 ± 100 to 1993 ± 399 
dyne • sec. cm -s, p = 0.01). There were no signifi- 
cant differences in the arterial blood gases between 
the groups. In both the L-NAME/control and L- 
NAME/DHCA animals, inhibition of nitric oxide 
synthase with L-NAME significantly increased PVR 
(Fig. 3, A and B). In the L-NAME/control piglets 
PVR increased from 526 + 53 dyne.  sec.  cm -5 
before L-NAME to 1813 + 253 dyne.  sec -cm +5 
20 minutes after L-NAME (p = 0.002). In the 
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Fig. 2. PVR changes in response to endothelium-dependent (acetylcholine, ACh) and endothelium- 
independent (nitric oxide, NO) vasodilators in control (A), U46619 (preconstricted with the thromboxane 
A 2 analog U46619) (B), and DHCA (C) animals. 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 6 
Kirshbom et al. 1 2 5 3 
2500 
2000 
=7 
E 
~ 1500 
= 
~ 1000. 
I!~ ~, 
~. 
500. 
0 
A 
.L 
["-~-- L-NAME/Controq 
I + ~ I 
0 5 10 20 30 
* p<0,01 ~s Time 0 Time (minutes) 
5000 
4500 
~ 4000. 
E 3500. 
~ 3000. 
~ 2500. 
• ~ 2000. 
~ 1500. 
I~ 
1000.  
500 - 
B 
• ~ 
# 
I ~ i ---F u I q 
P re -DHCA 0 5 10 20 30 
T ime (minutes)  
# p<0.01 Time 0 ~s Pre-DHCA, * p<0.01 vs Time 0 
Fig. 3. Effects of nitric oxide synthase inhibition before (A) and after (B) CPB with DHCA. Inhibition of 
nitric oxide production significantly increases PVR both at baseline and after DHCA. 
Table I. Arterial blood gases for protocol 1 
Paco 2 Pao 2 Alveolar-arterial 
pH (mm Hg) (ram Hg) Hematocrit gradient (mm Hg) 
Control 7.40 ± 0.01 38.6 ± 0.6 208 _+ 12 0.23 ± 0.01 74 ± 7 
U46619 7.40 _+ 0.03 36.7 _+ 1.1 210 _+ 3 0.27 ± 0.02 50 _+ 5 
DHCA 7.43 ± 0.01 37.3 _+ 0.8 195 _+ 9 0.25 ± 0.06 113 ± 23* 
*p < 0.025 versus U46619 (unpaired t test); no other significant differences. 
L-NAME/DHCA animals, PVR was 1993 _+ 399 
dyne • sec • cm ±s before L-NAME and 3895 _+ 654 
dyne • sec. cm -5 20 minutes after L-NAME (p = 
0.008); these results demonstrate that nitric oxide 
synthase in puhnonary endothelial cells continues to 
function and produce significant quantities of nitric 
oxide after CPB with DHCA. After blockade of 
nitric oxide synthase with I:NAME, PVR increased 
to a much higher level in the L-NAME/DHCA 
animals than in the L-NAME/control animals, sug- 
gesting that the pulmonary vasomotor tone in the 
absence of nitric oxide has changed. This finding is 
consistent with previous studies demonstrating in- 
creased production of vasoconstrictors after CPB. 7-9 
Effects of L-arginine supplementation on post- 
CPB pulmonary hypertension (protocol 4). Supple- 
mentation with L-arginine during CPB resulted in a 
slightly lower PVR relative to the no-L-arginine 
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Table IIA. Hemodynamic data in protocols 1 and 2 
Cardiac output (rnI/rnin) 
Pre -A CH A CH Pre-NO NO Pre -A CH 
Mean PAP (ram Hg) 
ACH Pre-NO NO 
Controls 1618 ± 103 1510 +_ 89 1602 ± 99 1602 ± 128 15.6 +_ 1.1 14.0 ± 0.5 14.8 ± 0.6 13.8 ± 0.4 
U46619 1188 ± 43 1387 +_ 98 1020 ± 50 1019 ± 90 32.7 ± 2.5 26.2 _+ 2.0* 31.8 ~+ 2.0 21.8 ± 2.27 
DHCA 845 ± 58 724 ± 68* 725 _+ 50 700 ± 63 25.5 ± 2.3 21.8 ± 1.7" 24.5 ± 1.9 17.5 ± 1.07 
PAP, Pulmonary artery pressure; ACH, acetylcholine; NO, nitric oxide; DHCA, deep hypothermic circulatory arrest. 
Significant at 95% by analysis of variance: *ACH versus pre-ACH. ?NO versus pre-NO. 
Table IIB. Hemodynamic data in protocol 3 
Cardiac output (ml/min) Mean PAP (ram Hg) 
L-NAME L-NAME 
Pre-L-NAME (20 min) Pre-L-NAME (20 rain) 
Controls 987 ± 70 873 ± 59 13.2 ___ 1.2 26.5 ± 3.3* 
DHCA 899 ± 125 520 ± 56* 25.5 ± 1.3 28.3 ± 2.1 
*p < 0.05 versus pre-L-NAME (paired t test). 
group (Fig. 4); however, this difference was not 
statistically significant (2404 +_ 436 vs 2980 _+ 515 
dyne • sec • cm -5, p = 0.4). These data suggest that 
I.-arginine deficiency does not play a major role in 
post-CPB pulmonary hypertension. There were no 
significant differences in the arterial blood gases 
between the two groups. 
Discussion 
Many factors contribute to the development of
pulmonary hypertension after CPB. The factors that 
control pulmonary vasomotor tone are not com- 
pletely understood and the effects of CPB on pul- 
monary vascular function have not been fully de- 
fined. The pulmonary endothelium produces both 
vasoconstrictors and vasodilators and is perhaps the 
most important determinant of pulmonary vascular 
tone. Previous tudies have demonstrated both fail- 
ure of pulmonary receptor-mediated endothelium- 
dependent vasodilatation e' 7 and increased produc- 
tion of vasoconstrictors after CPB. 7-1° This study 
used an intact piglet model to assess the effect of 
CPB on endothelium-dependent vasodilatation. In 
this model, CPB with DHCA results in the loss of 
receptor-mediated endothelium-dependent vasodi- 
latation with preservation of endothelium-indepen- 
dent vasodilatation. Wessel and colleagues  demon- 
strated that pulmonary vasodilatation in response to 
nitric oxide was intact in children studied after CPB, 
whereas acetylcholine-mediated vasodilatation was 
markedly diminished. Thus the pattern of injury in 
this experimental model is similar to that observed 
clinically. However, loss of the vasodilatory esponse 
Table IIC. Hemodynamic data in protocol 4 
Cardiac output (ml/min) Mean PAP (ram Hg) 
Pre-DHCA Post-DHCA Pre-DHCA Post-DHCA 
No L-arginine 961 ± 61 744 ± 79 14.6 ± 1.1 32.1 +_ 1.1" 
L-Arginine 1136 ± 94 795 ± 63* 15.4 ± 1.1 29.0 +_ 2.8* 
*p < 0.05 versus pre-DHCA (paired t test). 
to acetylcholine by the pulmonary vasculature does 
not necessarily mean that pulmonary vascular endo- 
thelial cells are incapable of producing nitric oxide. 
This study demonstrates that the pulmonary endo- 
thelium continues to produce significant quantities 
of nitric oxide after CPB, suggesting that nitric oxide 
synthase is functional despite loss of acetylcholine- 
mediated vasodilatation. Although these studies 
clearly demonstrate continued production of signif- 
icant quantities of nitric oxide after DHCA, the 
assays used are not quantitative; thus the actual 
amount of nitric oxide produced could still be 
diminished. 
Vasodilatation i response to receptor-mediated 
endothelium-dependent vasodilators such as acetyl- 
choline depends on a sequence of events beginning 
with binding of the agonist o a membrane bound 
receptor and ending with smooth muscle relaxation 
(see Fig. 1). 4, 5 Previous experiments have shown 
that the muscarinic receptor on the endothelial cell 
surface is coupled via a G protein to the enzyme 
phospholipase C. TM 12 Stimulation of phospholipase 
C initiates the phosphatidylinositol pathway leading 
to a rise in intracellular calcium and increased 
conversion of I~-arginine to nitric oxide by nitric 
oxide synthase. The nitric oxide then diffuses to the 
vascular smooth muscle, causing an increase in 
cyclic guanosine monophosphate production and 
smooth muscle relaxation. Dysfunction at any of 
these intermediary steps would result in failure of 
vasodilatation in response to acetylcholine. 
Previous tudies have demonstrated that endothe- 
lial injury may result in a selective failure of recep- 
tor-mediated endothelium-dependent vasodilata- 
The Journal of Thoracic and 
Cardiovascular Surgery 
Volume 111, Number 6 
Kirshbom et aL 1 2 5 5 
3500 
3000 
~: 2500 
? 
tJ 
m 2000 (~ 
$ 
~- 
>, 1500 
'O 
~, 1000 
500 
• No L-arg 
E] L-a rg 
Pre-DHCA Post-DHCA 
* p=-0.45 vs No L-arg 
Fig. 4. Effects of L-arginine supplementation on post-DHCA PVR. 
tion with preserved ability to produce nitric oxide. I3 
Evora, Pearson, and Schaff 5evaluated endothelium- 
dependent vasodilatation i  canine coronary arter- 
ies after global ischemia. Using in vitro coronary 
artery rings, they demonstrated loss of receptor- 
mediated endothelium-dependent vasodilatation 
with preservation of the responses to the receptor- 
independent endothelium-dependent vasodilators 
A23187 and phospholipase C. In these studies there 
was diminished response to sodium fluoride, which 
activates G proteins directly, demonstrating specific 
G protein dysfunction after ischemia/reperfusion. 
Seccombe, Pearson, and Schaff 12 showed that expo- 
sure of isolated coronary artery rings to oxygen- 
derived free radicals also results in a G protein 
injury that produces a selective impairment of re- 
ceptor-mediated ndothelium-dependent vasodila- 
tation. A similar pattern of endothelial injury has 
been reported in early atherosclerosis. 14 G proteins 
have also been shown to be involved in the regula- 
tion of nitric oxide production in response to 
changes in shear stress. 15' 16 Thus a G protein injury 
could result in dysfunctional endothelial vasoregu- 
lation. Shafique and colleagues 7 have demonstrated 
in an in vitro model that after CPB acetylcholine 
may cause vasoconstriction rather than vasodilata- 
tion in isolated pulmonary vessels. The mechanism 
of this change is unknown but may be due to 
production of a vasoconstricting prostanoid. 
The current study demonstrates that in this in vivo 
animal model, CPB with DHCA produces failure of 
receptor-mediated endothelium-dependent vasodi- 
latation in the pulmonary vasculature with pre- 
served ability to produce nitric oxide. This finding is 
consistent with clinical studies demonstrating an 
impaired response to acetylcholine with preserved 
response to inhalational nitric oxide. 2' 3, 17 The cur- 
rent study shows that the impaired response to 
acetylcholine is not due to smooth muscle dysfunc- 
tion, failure of nitric oxide synthase, or nitric oxide 
synthase substrate (L-arginine) limitation. These ob- 
servations uggest hat CPB produces a selective 
pulmonary endothelial injury. The data suggest that 
the defect causing failure of receptor-mediated en-
dothelium-dependent vasodilatation occurs up- 
stream of nitric oxide synthase and hence might be 
located at the level of the receptor, G protein, or 
phospholipase C second messenger system (see Fig. 
1). Previous tudies have demonstrated selective G 
protein dysfunction in the coronary artery after 
global ischemia or exposure to oxygen-derived free 
radicals.S, 12 The findings of the current study sug- 
gest hat a similar injury may occur in the pulmonary 
vasculature, impairing the ability of the endothelial 
cell to modulate vasomotor tone and leading to an 
imbalance between vasoconstrictors and vasodila- 
tors. 
The current study has several limitations. The use 
of an intact animal model mimics the clinical situa- 
tion more closely than isolated vessel preparations. 
However, inasmuch as important variables uch as 
changing intravascular shear stress and the interac- 
tions between blood elements and the endothelium 
are included, these variables cannot be tightly con- 
trolled. Also, the experimental model directly as- 
sesses neither G protein function nor the role of 
increased vasoconstrictor p oduction during CPB. 
Endothelium-derived vasoconstrictors, including 
thromboxane A 2 and endothelin 1,have been shown 
to be important in post-CPB pulmonary hyperten- 
12 5 6 Kirshbom et aL 
The Journal of Thoracic and 
Cardiovascular Surgery 
June 1996 
sion. 7-1° The level of vasoconstriction after I~- 
NAME was much greater in animals after DHCA 
than in controls, suggesting that the basal tone in the 
absence of nitric oxide is higher after DHCA, pos- 
sibly because of increased vasoconstrictor levels. 
Also, although these studies demonstrate a specific 
defect in muscarinic receptor-mediated nitric oxide 
production, other receptor systems may be unaf- 
fected. 
In summary, we have used an intact animal model 
to examine pulmonary endothelial function after 
CPB. The findings are consistent with prior clinical 
studies and suggest hat there is a specific impair- 
ment of receptor-mediated endothelium-dependent 
vasodilatation with continued production of nitric 
oxide by the endothelium and preserved vascular 
smooth muscle response to nitric oxide. It must be 
emphasized that although these studies demonstrate 
continued nitric oxide production after DHCA, 
these assays are not quantitative; thus the amounts 
of nitric oxide produced may well be decreased. In 
conclusion, this study suggests that CPB disrupts 
some of the regulatory functions of the endothelial 
cell, alters the balance between vasoconstriction a d 
vasodilatation, and ultimately results in pulmonary 
hypertension. 
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